December 10, 2021 -- Pacific BioSciences (PacBio), the Institute for Precision Health at the University of California, Los Angeles (UCLA), and UCLA's David Geffen School of Medicine have formed a research collaboration to further identify the causes of rare diseases. The collaboration aims to identify variants not easily detectable by short-read sequencing.
The study will leverage PacBio's HiFi long-read sequencing technology for whole genome sequencing (WGS) in undiagnosed pediatric rare disease patients who have already been sequenced with short-read technology.
Dr. Stanley Nelson, director of the California Center for Rare Diseases and a professor at the David Geffen School of Medicine, will use full-length isoform sequencing and long-read WGS to investigate the effect on diagnostic yield in unresolved cases.
"For rare disease patients, a genetic diagnosis always provides clarity to the whole family and can mean more effective treatments to avoid long-term complications," Nelson explained.
"Within our undiagnosed diseases program at UCLA, approximately 50 percent of the rare disease patients we conduct short-read WGS on will still not have a DNA diagnosis. We hope that the knowledge we gain will allow us to reduce that number and give more families a diagnosis," Nelson added.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
